Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG in severe COVID-19 pneumonia
NCT04261426Phase 3Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of intravenous immunoglobulin G in COVID-19 pneumonia (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Clinical improvement based on the 7-point scale at 28 days and Lower Murray lung injury score at 14 days. Status: unknown.
02
Drugs
intravenous immunoglobulin G
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04261426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261426.